Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Reximmune-C2 by GenVivo for Breast Cancer: Likelihood of Approval
Reximmune-C2 is under clinical development by GenVivo and currently in Phase I for Breast Cancer. According to GlobalData, Phase I...